Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Study on the Safety, Tolerability and Pharmacokinetic Characteristics of GMDTC for Injection After Repeated Administration in People With Excessive Cadmium Levels

NCT06199349 is registered in ClinicalTrials.gov with Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06199349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06199349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Study on the Safety, Tolerability and Pharmacokinetic Characteristics of GMDTC for Injection After Repeated Administration in People With Excessive Cadmium Levels
Lead sponsor
Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 8, 2024
Completion date
December 5, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cadmium exceeds the standard